Patents Assigned to Baylor College of Medicine
  • Publication number: 20190125176
    Abstract: One aspect of the invention provides a trocar including: a central cylinder defining a central channel and having a distal end adapted and configured for insertion within a subject; one or more gas outlets located within the central cylinder proximate to the distal end of the trocar; and one or more liquid outlets located within the central cylinder on a proximal side of the one or more gas outlets. The one or more liquid outlets are adapted and configured to dispense a liquid when an endoscope is withdrawn from a fully extended position within the central channel of the trocar to a position proximate to the one or more liquid outlets. Distal advancement of the endoscope to a position adjacent to the one or more gas outlets removes liquid from a distal end of the endoscope.
    Type: Application
    Filed: April 13, 2017
    Publication date: May 2, 2019
    Applicants: Baylor College of Medicine, Texas Heart Institute
    Inventors: Bryan M. Burt, Mahmood Khan, William Cohn
  • Patent number: 10265315
    Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: April 23, 2019
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Bert W. O'Malley, David Michael Lonard, Jin Wang, Jianming Xu, Jianwei Chen
  • Patent number: 10260100
    Abstract: The present invention relates to neuropathy, in particular to mutations in the FIG4 gene. The present invention also provides assays for the detection of variant FIG4 alleles, and assays for detecting FIG4 polymorphisms and mutations associated with disease states.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: April 16, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, BAYLOR COLLEGE OF MEDICINE
    Inventors: Miriam Meisler, James R. Lupski, Clement Chow
  • Publication number: 20190105470
    Abstract: One aspect of the invention provides a sheath including: a cylinder defining a central passage; a balloon located along an external surface of a distal end of the cylinder, the balloon lying substantially flush with or recessed from the external surface when deflated, but capable of projecting beyond the external surface when inflated; and an inflation port located at a proximal end of the cylinder, the inflation port in fluid communication with the balloon. Another aspect of the invention provides a kit including: a sheath as described herein and instructions for use.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 11, 2019
    Applicant: Baylor College of Medicine
    Inventors: Naveen Yadav, Arun Rai, Christopher Graziano, Samit Soni, Richard Link
  • Patent number: 10251778
    Abstract: A therapeutics delivery system, and methods of making and using same, are disclosed for environments that rapidly clear any injected therapeutics, such as a patient's eye. The therapeutics delivery system releases the drug in a therapeutically effective concentration for a desired duration of time with a predefined drug kinetics. In one embodiment, the embodiments of the present disclosure release a therapeutically effective concentration for a longer time period than other delivery systems, for instance from a day to a week. Certain embodiments comprise a therapeutics dispensing device comprising a biodissolvable hydrogel matrix for long term drug release that allows the device to be placed directly at the injured site, e.g., onto the surface at or near the injury, and retained there rather than through injection, whether locally or systematically.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: April 9, 2019
    Assignees: Baylor College of Medicine, REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ghanashyam Acharya, Stephen C. Pflugfelder, Cintia S. De Paiva, Jennifer L. Simpson
  • Patent number: 10246560
    Abstract: Embodiments of the invention concern copolymers and nanoparticles for use as delivery agents for one or more agents for therapy for a medical condition of humans and animals. Some of embodiments of the invention provide new reagents for biomedical research in cell culture, animal models and plants, for example. The copolymers comprise PLGA and PEI and, in some embodiments, also comprise 1-(3-aminopropyl)-4-methylpiperazine (APMP), Fc binding peptide and/or antibody. In certain embodiments, APMP-PLGA-PEI, Fc binding peptide/antibody-PLGA-PEI or Fc binding peptide/antibody-AP-MP-PLGA-PEI nanoparticles comprising one or more therapeutic agents are delivered to an individual in need thereof or used for biomedical research in cell cultures, animal models and plants.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Baylor College of Medicine
    Inventors: Jian-Ming Lu, Qizhi Yao, Changyi Chen
  • Patent number: 10246496
    Abstract: Novel analogues of the sea anemone Stichodactyla helianthus toxin ShK, and their use as, for example, therapeutic agents for treating autoimmune diseases are disclosed. The analogues comprise a ShK toxin polypeptide and an N-terminal extension comprising an amino acid sequence according to formula (I): wherein X?4 is D, E or other negatively-charged amino acid or derivative thereof, X?3 is E, I, L, S, V, W or a tryptophan derivative, X?2 is any amino acid, X?1 is any amino acid, a is absent or a first additional moiety, and b is absent or a second additional moiety.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: April 2, 2019
    Assignees: LA TROBE UNIVERSITY, MONASH UNIVERSITY, BAYLOR COLLEGE OF MEDICINE, PEPTIDES INTERNATIONAL, INC.
    Inventors: Raymond S. Norton, Shih Chieh Chang, Michael W. Pennington, Christine Beeton, Brian J. Smith
  • Patent number: 10227656
    Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRD1. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRD1 is overexpressed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 12, 2019
    Assignee: Baylor College of Medicine
    Inventors: Bin He, Rainer B. Lanz, Nicholas Mitsiades, Qin Feng
  • Publication number: 20190046569
    Abstract: Embodiments of the disclosure concern methods and compositions related to cancer therapy using myeloid derived suppressor cells (MDSC) as a solo therapy or an adjunct therapy. The MDSCs are prepared by exposing bone marrow cells or blood cells to one or more compositions that induce their differentiation to MDSCs and also to TGF-?1, and in specific embodiments the exposure to TGF-?1 results in the MDSCs having anti-tumor activity and/or immune stimulatory activity.
    Type: Application
    Filed: September 14, 2016
    Publication date: February 14, 2019
    Applicant: Baylor College of Medicine
    Inventors: Andrew SIKORA, Padmini JAYARAMAN, Falguni PARIKH, Robin PARAHIR
  • Publication number: 20190000609
    Abstract: When zonular attachments of a capsule holding an implanted lens weaken after cataract surgery, a capsular clip may be utilized to secure the capsular bag to the eye wall. The capsular clip may comprise an eyelet and a flat hook. The hook may be inserted either via a small surgeon created separation between the anterior capsule leaflet and the intraocular lens or via puncturing the capsular bag in a small area, and may be placed between the capsular bag and the implanted lens to secure the capsule in the appropriate position within the eye. Suture thread may be fed through the eyelet of the capsular clip to sew the capsular clip to the eye wall, thus securing the capsular clip and the capsule in place.
    Type: Application
    Filed: December 15, 2016
    Publication date: January 3, 2019
    Applicant: Baylor College of Medicine
    Inventor: Marshall Bowes Hamill
  • Publication number: 20180360365
    Abstract: One aspect of the invention provides an autonomous continuous bladder irrigation device including: a color sensor programmed to detect a color of outflow from a catheter; an occlusion unit programmed to adjustably occlude a lumen providing irrigation to the catheter; and a controller in communication with the color sensor and the occlusion unit and programmed to control the occlusion unit to titrate irrigation flow to the catheter based on the color detected by the color sensor in order achieve a specified color of outflow from the catheter.
    Type: Application
    Filed: December 21, 2016
    Publication date: December 20, 2018
    Applicant: Baylor College of Medicine
    Inventors: Naveen Yadav, Arun Rai
  • Publication number: 20180344828
    Abstract: Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.
    Type: Application
    Filed: October 31, 2016
    Publication date: December 6, 2018
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Baylor College of Medicine
    Inventors: Lauren V. Wood, Brenda D. Roberson, Jay A. Berzofsky, John C. Morris, Jason C. Steel, Masaki Terabe, Malcolm K. Brenner
  • Patent number: 10119141
    Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: November 6, 2018
    Assignees: Baylor College of Medicine, Texas Heart Institute
    Inventors: James F. Martin, Yuka Morikawa, Todd Ryan Heallen, John Leach
  • Patent number: 10117942
    Abstract: Embodiments of photoactivatable, lipid-based nanoparticles are disclosed, as well as methods of making and using the nanoparticles. Pharmaceutical compositions including the nanoparticles also are disclosed. The lipid-based nanoparticles include a vesicle wall surrounding a cavity, wherein the vesicle wall includes (i) a lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), dipalmitoylphosphatidylcholine (DPPC), and (ii) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer. The nanoparticles may further include an agent within the cavity.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: November 6, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Baylor College of Medicine
    Inventors: Anu Puri, Robert P. Blumenthal, Amit Joshi, Darayash B. Tata, Mathias Viard
  • Patent number: 10112933
    Abstract: Embodiments of the invention include methods of treating, preventing, and/or reducing the risk of fibrosis in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction of the risk of fibrosis. In at least particular cases, the small molecules are inhibitors of STAT3.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: October 30, 2018
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: David J. Tweardy, Moses M. Kasembeli, Marvin X. Xu, Sandeep K. Agarwal, Mesias Pedroza
  • Patent number: 10092532
    Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: October 9, 2018
    Assignee: Baylor College of Medicine
    Inventor: Brendan Lee
  • Publication number: 20180271863
    Abstract: Embodiments of the present disclosure pertain to methods of inhibiting cancer cells by exposing the cancer cells to a purinergic receptor antagonist that targets one or more purinergic receptors of the cancer cells. The targeted purinergic receptors can include P2 purinergic receptors, such as P2X purinergic receptor subtypes (e.g., P2X3 or P2X5) and P2Y purinergic receptor subtypes (e.g., P2Y2). In some embodiments, the inhibited cancer cells are associated with hepatocellular carcinoma. In additional embodiments, the present disclosure pertains to methods of treating hepatocellular carcinoma in a subject by administering a purinergic receptor antagonist to the subject such that the antagonist targets one or more purinergic receptors of hepatocellular carcinoma cells in the subject. In some embodiments, the subject is a human being suffering from hepatocellular carcinoma.
    Type: Application
    Filed: October 24, 2016
    Publication date: September 27, 2018
    Applicant: Baylor College of Medicine
    Inventors: Sundararajah Thevananther, Janielle P. Maynard
  • Patent number: 10082510
    Abstract: Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: September 25, 2018
    Assignee: Baylor College of Medicine
    Inventors: Bert W. O'Malley, Subhamoy Dasgupta, Nicholas Mitsiades, Arun Sreekumar, Sean E. Mcguire
  • Publication number: 20180265444
    Abstract: Small molecule stimulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing cancer. Also provided are methods for stimulating SRC family proteins in a cell.
    Type: Application
    Filed: December 29, 2015
    Publication date: September 20, 2018
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: David Michael Lonard, Lei Wang, Bert W. O'Malley, Jianming Xu, Yongcheng Song, Xiaonan Li, Timothy Gerald Palzkill
  • Patent number: 10052310
    Abstract: In some embodiments, the present disclosure pertains to compositions with compounds that inhibit Separase activity. In additional embodiments, the present disclosure pertains to methods of treating a tumor in a subject by administering one or more compositions of the present disclosure to the subject.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: August 21, 2018
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Debananda Pati, Nenggang Zhang